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Introduction
In 2014, McEvoy and colleagues reported results 
of the first double-blind comparison between a 
first- and second-generation long-acting injec-
tion.1 The study, comparing paliperidone palmi-
tate (PPLAI) and haloperidol decanoate 
(HDLAI), found no overall difference in efficacy 
between the two treatments. Haloperidol in this 
study was used in strict accordance with a pre-
scribed loading regimen and maintenance doses 
were lower than traditionally seen in practice. 
The incidence of specific adverse effects varied 
between the drugs, however, overall tolerability of 
both was broadly comparable: paliperidone was 
associated with more weight gain and higher 
serum prolactin levels and haloperidol was associ-
ated with more akathisia and the use of anticho-
linergic medication.
Separately, observational data for PPLAI from 
our own unit showed a reduction in both the 
number of hospital admissions and inpatient bed 
days in the 2 years after discharge compared with 
the 2 years before paliperidone initiation.2 At 1 
year, 65% of patients remained on the PPLAI.3
PPLAI is considerably more expensive than 
HDLAI. Based on the findings by McEvoy and 
co-workers that HDLAI is as effective and well 
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Abstract
Background: We sought to determine clinical outcomes of the prescribing of haloperidol 
decanoate long-acting injection (HDLAI) at 1 year.
Method: A 1-year mirror-image study of 84 inpatients initiated on HDLAI. Admissions and bed 
days in the year preceding HDLAI were compared with the year after initiation. Predictors for 
discontinuation were evaluated.
Results: At 1 year, 33% of patients remained on treatment. Patients starting HDLAI because 
of nonadherence were more likely to stop treatment [relative risk (RR) 1.72; 95% confidence 
interval (CI) 1.01, 2.91; p = 0.044] whilst patients with a longer duration of illness were 
more likely to remain on treatment (RR 0.88; 95% CI 0.78, 1.00; p = 0.050). In the bed days 
cohort overall, (n = 65), there was a significant reduction in mean hospital admissions (1.4/
patient/year to 0.6/patient/year; p = 0.0001) but not bed days (55.6/patient to 45.0/patient; p 
= 0.07) in the year following HDLAI initiation compared with the year before. Continuers had 
a significant reduction in mean bed days (53.1 to 4.0; p = 0.0002) and hospital admissions 
(1.5 to 0.2; p = 0.0001). Discontinuers demonstrated a significant reduction in hospital 
admissions (1.5 to 0.8; p = 0.0001) but not bed days (56.7 to 64.5; p = 0.83).
Conclusion: HDLAI was associated with a high treatment discontinuation rate. Hospital 
admissions fell in the year after HDLAI but there was no change in bed days. Our study 
suggests that patients with a longer duration of illness and patients initiated on HDLAI for 
reasons other than poor adherence may benefit from HDLAI initiation.
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tolerated as PPLAI, we changed our trust pre-
scribing guidelines to include the recommenda-
tion that HDLAI be considered the long-acting 
injection of choice.
In this paper, we report the discontinuation rate, 
hospital bed days and admissions at 1 year for 
inpatients who started HDLAI between June 
2014 and June 2015 in the South London and 
Maudsley NHS Foundation Trust.
Materials and method
All inpatients starting HDLAI between July 2014 
and July 2015 were identified and followed for 1 
year. HDLAI is supplied for inpatients from the 
trust pharmacy on submission of a valid prescrip-
tion. Inpatients starting HDLAI were identified 
from these prescriptions. Demographic data and 
medication details were recorded from patients’ 
electronic medical notes, pharmacy notes and 
prescription charts. Medication details included 
the recorded reason for initiation of HDLAI, 
antipsychotic prescribed immediately before 
HDLAI and immediately after in those who 
stopped, reason for stopping treatment, reported 
adverse effects and a history of previous clozapine 
or HDLAI treatment. Initiation and maintenance 
doses and the haloperidol initiation regimen were 
recorded from the prescription. Patient data once 
collected were anonymised and stored in a secure 
database.
Ethics approval was not sought for the purpose 
of this study. The study was approved by the 
trust’s Drug and Therapeutics Committee, the 
locally designated approval committee. Our 
standard method had previously been assessed 
by our local ethical committee as not requiring 
ethical committee approval because treatment 
was not affected by our method and because 
data were anonymised. The decision to initiate 
HDLAI was an independent prescribing deci-
sion; this study did not influence clinical prac-
tice. Patient-identifiable data accessed for the 
purpose of data collection are readily available 
to clinicians involved in the study as part of 
their normal working practice. Patients were 
not required to give informed consent to the 
study.
Primary analysis
Our primary outcome was discontinuation with 
treatment at 1 year.
Secondary analyses
Change in admissions and bed days following treat-
ment with HDLAI. We used a mirror-image study 
design to compare the number of hospital admis-
sions and occupied hospital bed days before and 
after HDLAI initiation. The mirror was placed in 
three different places as previously described.2 In 
our main analysis, we compared the number of 
admissions and bed days in the year before halo-
peridol initiation with the year after discharge 
from the admission during which haloperidol was 
initiated (index admission), thus including the 
index admission only until HDLAI initiation and 
disregarding the remainder of the admission (see 
Figure 1).
Sensitivity analyses
We conducted two sensitivity analyses: In the 
first, the ‘mirror’ was placed at the point of initia-
tion of haloperidol, including the entire index 
admission. In the second, the entire index admis-
sion was disregarded and the mirror placed at 
both the point of admission to and discharge from 
the index admission (see Figure 1).
Figure 1. Schematic representation of the mirror-image method of the analyses. Shaded areas were disregarded.
HDLAI, haloperidol decanoate long-acting injection.
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Patients on forensic inpatient units were excluded 
from the analyses of admissions and bed days 
because their hospital stay is determined by the 
Ministry of Justice and may be independent of 
their clinical presentation.
Statistical analysis
All analyses were performed using STATA ver-
sion 11.2 (StataCorp LP, College Station, Texas, 
USA).
Treatment discontinuation
Time to discontinuation of HDLAI was the out-
come of interest. Patients were followed up for 
365 days from the date of initiation of HDLAI 
until they discontinued treatment or dropped out 
of the study. Patients were regarded as discon-
tinuers if they switched to another antipsychotic, 
stopped HDLAI or if the next HDLAI dose was 
not administered within 8 weeks of the last dose. 
Patients were regarded as continuers if they 
received uninterrupted treatment with HDLAI 
until the end of the follow-up period. We defined 
censoring as absence of the event at time of death 
or loss to follow up before the end of the study 
period. Patient baseline demographics at the time 
of initiation were summarized using descriptive 
statistics. Time to discontinuation was modelled 
using a multivariate Cox regression model. We 
first screened baseline variables (age, sex, ethnic-
ity, diagnosis, duration of illness, treatment 
responsiveness, previous use of HDLAI, initia-
tion regimen and reasons for initiating treatment) 
using a univariate Cox regression model and vari-
ables showing a significant association (p < 0.2) 
were included in the multivariate model. 
Categorical variables with multiple levels were 
collapsed prior to the regression analyses in order 
to avoid cells with sparse data. Continuous vari-
ables were assessed for linearity using Martingale 
residual plots and transformed using fractional 
polynomials.4 The proportional hazard assump-
tion for each variable was tested using Schoenfeld 
residuals by time plots. Goodness of fit was 
assessed by Cox–Snell residual plots.
Hospital admissions and bed days
We expected hospital admissions and bed 
days to be non-normally distributed, therefore we 
used nonparametric tests to analyse outcomes 
before and after treatment. Comparisons before 
and after were performed using the Wilcoxon 
signed-rank test for paired data. We conducted a 
Mann–Whitney U test to compare outcomes 
between continuers and discontinuers. A statisti-
cally significant change was determined by a p 
value less than 0.05.
Results
Baseline patient characteristics
In total, 84 patients started HDLAI during the 
study period. Three patients were lost to follow 
up and two patients died during the study period. 
Neither death was considered to be associated 
with HDLAI treatment. Baseline patient charac-
teristics and reasons for HDLAI initiation are 
shown in Table 1.
Haloperidol initiation and discontinuation
Antipsychotic prescribed immediately before 
HDLAI, reasons for HDLAI discontinuation and 
antipsychotic prescribed immediately after 
HDLAI are shown in Table 2.
At 1 year, 28 patients (33%) remained on treat-
ment (Figure 2). Median survival time for the 
whole group was 235 days [95% confidence inter-
val (CI) 145–303 days]. Among the group, 77 
(92%) patients received at least one monthly 
maintenance dose of HDLAI. The median 
monthly maintenance dose for the total cohort 
was 75 mg: 87.5 mg for continuers and 75 mg for 
discontinuers.
Adverse effects
The following adverse effects were reported in the 
patients who discontinued treatment because of 
adverse effects: Extrapyramidal side effects 
(EPSEs) (62%), restlessness (14%), weight gain 
(10%), hypersalivation (10%), lack of sleep (5%), 
sexual dysfunction (5%), constipation (5%), uri-
nary incontinence (5%), cessation of menstrua-
tion (5%), discomfort (5%), fatigue (5%), pain 
(5%), abscess at injection site (5%), skin allergy 
(5%), chest pain (5%), sedation (5%), reduced 
sensation in hands (5%).
Predictors for discontinuation with haloperidol
Of all variables screened in the univariate anal-
ysis ethnicity, nonadherence to previous treat-
ment and illness duration were significantly 
associated with treatment discontinuation. The 
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Table 1. Baseline patient characteristics and reasons for HDLAI initiation.
Characteristic Total cohort
(n = 84)
n (%)
Discontinued
(n = 56)
n (%)
Continued
(n = 28)
n (%)
Age at initiation (years)
 Mean (SD) 40.5 (11.7) 39.5 (11.5) 42.5 (12.1)
 Median (min, max) 41 (20, 70) 38.5 (20, 64) 43 (22, 70)
Sex
 Male 43 (51) 29 (52) 14 (50)
 Female 41 (49) 27 (48) 14 (50)
Ethnicity
 White 20 (24) 9 (16) 11 (39)
 Black 51 (61) 38 (68) 13 (46)
 Other 13 (15) 9 (16) 4 (14)
Diagnosis
 Schizophrenia 49 (58) 32 (57) 17 (60)
 Schizoaffective disorder 17 (20) 9 (16) 8 (28)
 Bipolar affective disorder 8 (10) 7 (13) 1 (4)
 Other 10 (12) 8 (14) 2 (8)
Duration of illness (years)
 Mean (SD) 14.2 (10.7) 12.9 (10.2) 16.7 (11.4)
 Median (min, max) 10.5 (0, 40) 9 (0, 40) 14 (2, 40)
Considered treatment resistant
 Yes 35 (42) 24 (43) 11 (39)
 No 49 (58) 32 (57) 17 (61)
Previous use of HDLAI
 Yes 11 (13) 7 (12) 4 (14)
 No 73 (87) 49 (84) 24 (86)
Initiation regimen
 Loaded 52 (62) 35 (63) 17 (61)
 Not loaded 19 (23) 13 (23) 6 (21)
 Loading not required 13 (15) 8 (14) 5 (18)
Reasons for HDLAI initiation
Patient request 5 (6) 0 5 (18)
Prior poor adherence 36 (43) 27 (48) 9 (32)
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Characteristic Total cohort
(n = 84)
n (%)
Discontinued
(n = 56)
n (%)
Continued
(n = 28)
n (%)
Prior poor response 13 (15) 13 (23) 0
Prior poor tolerability 14 (17) 6 (11) 8 (29)
Other reasons 10 (12) 7 (13) 3 (11)
Not stated 6 (7) 3 (5) 3 (11)
HDLAI, haloperidol decanoate long-acting injection; SD, standard deviation.
Table 1. (Continued)
Table 2. Antipsychotic prescribed immediately before 
haloperidol decanoate long-acting injection (HDLAI), 
reasons for HDLAI discontinuation and antipsychotic 
prescribed immediately after HDLAI.
Antipsychotic prescribed 
immediately before 
haloperidol (n = 84)
n (%)
Oral atypical 51 (61)
Oral typical 9 (11)
Depot atypical 9 (11)
Depot typical 3 (3)
Clozapine 5 (6)
Antipsychotic 
polypharmacy
5 (6)
None 2 (2)
Reasons for discontinuation (n = 56)
Adverse effects 21 (25)
Poor response 15 (18)
Patient choice 17 (20)
Other 3 (4)
Antipsychotic prescribed immediately after 
haloperidol (n = 56)
Oral atypical 17 (30)
Oral typical 6 (11)
Depot atypical 11 (20)
Depot typical 0
Clozapine 10 (18)
Antipsychotic 
polypharmacy
2 (3)
No antipsychotic 10 (18)
results of the multivariate Cox regression 
model showed that risk of discontinuation was 
significantly increased by initiation due to non-
adherence (versus other reasons for initiation) 
and decreased by longer duration of illness 
(Table 3).
Analyses of hospital admissions and bed days
In total, 65 patients (excluding forensic patients, 
patients lost to follow up and patients who died) 
were included in the analyses of bed days and 
admissions. In our main analysis, there was a sig-
nificant reduction in the number of admissions in 
the year after HDLAI initiation compared with 
the year before (1.4/patient/year to 0.6/patient/
year; p = 0.0001). There was a nonstatistically 
significant reduction in mean bed days from 55.6/
patient to 45.0/patient (p = 0.07) for the same 
period.
Patients who continued (n = 21) HDLAI for a 
year had a significant reduction in mean bed 
Figure 2. Treatment discontinuation during first year 
of treatment.
CI, confidence interval.
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days (53.1 to 4.0; p = 0.0002) and hospital 
admissions (1.5 to 0.2; p = 0.0001) after 
HDLAI, compared with the year before treat-
ment. Discontinuers (n = 44) demonstrated a 
significant reduction in the number of admis-
sions (1.5 to 0.8; p = 0.0001) and a nonstatisti-
cally significant increase in mean bed days 
(56.7/patient to 64.5/patient; p = 0.8336) for 
the same period. See Figures 3 and 4. The 
mean number of beds days between initiation 
of HDLAI and discharge from the index admis-
sion was 51.
Sensitivity analyses
In sensitivity analysis 1 (when the entire index 
admission was included) there was a significant 
increase in the mean number of bed days (55.6 to 
85.7; p = 0.007) and a significant reduction in mean 
hospital admissions (1.4 to 0.5; p = 0.0001) in the 
year following HDLAI initiation compared with the 
year before. In sensitivity analysis 2 (disregarding the 
entire index admission) there was a nonstatistically 
significant increase in mean bed days (22.8 to 
45.0; p = 0.086) and no change in mean hospital 
admissions (0.6 to 0.6; p = 0.9915).
Table 3. Cox regression model results.
Variable Univariate Multivariate
HR 95% CI p value HR 95% CI p value
Ethnicity  
Black 1.62 0.92, 2.83 0.094 1.70 0.97, 2.99 0.065
Other (reference) 0  
Reason for initiation  
Non-adherence 1.71 1.01, 2.90 0.045 1.72 1.01, 2.91 0.044
Other reasons (reference) 0  
Duration of illness (years)* 0.89 0.78, 1.01 0.068 0.88 0.78, 1.00 0.050
*For ease of interpretation, HRs are for each 5-year increase in duration of illness (as opposed to 1-year increase). The 
result translates to 11% reduced risk of discontinuation for 1–5 years duration of illness compared with duration of 
illness < 1 year or 20% reduction in risk for 6–10 years duration compared with <1 year duration of illness.
HR, hazard ratio; CI, confidence interval.
Figure 3. Mean reduction in bed days before and after haloperidol decanoate long-acting injection (main 
analysis).
Significant p values are shown in bold.
HDLAI, haloperidol decanoate long-acting injection.
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Discussion
In this mirror-image study, only a third of patients 
who started haloperidol remained on it at 1 year. 
Haloperidol initiation was associated with a sig-
nificant reduction in the mean number of hospital 
admissions. There was no change in the mean 
number of bed days.
The two main reasons for discontinuation were 
adverse effects and patient choice. EPSEs were 
the most commonly reported adverse effect lead-
ing to discontinuation.
Initiation of haloperidol because of nonadherence 
was associated with an increased risk of treatment 
discontinuation and increased duration of illness 
was associated with a decreased probability of 
discontinuation. Age, diagnosis, sex, ethnicity, 
initiation regimen or maintenance dose did not 
predict continuation with treatment.
Bed days and hospitalizations
Outcomes in mirror-image studies are strongly 
influenced by study design. Researchers must 
decide at which point during the inpatient admis-
sion to ‘place’ the mirror: Previous naturalistic 
studies have included part, all or none of the index 
admission. In our main analysis, we positioned the 
mirror at the point of depot initiation and at dis-
charge from the index admission. This method, as 
described by Taylor and colleagues,2 is suggested 
to be a fair assessment, as it assigns all hospital 
admissions and bed days before initiation of halo-
peridol to the previous treatment whilst disregard-
ing the remainder of the admission, thus allowing 
time for development of response to the new treat-
ment. This method assumes that patients respond 
to the new treatment and are promptly discharged. 
In the present study, the mean number of bed 
days during the index admission after HDLAI ini-
tiation was similar to the mean bed days in the 
entire year preceding HDLAI initiation. This 
means that our main analysis discounted a large 
number of bed days which might justifiably have 
been allocated to HDLAI treatment. Hence the 
decrease in bed days seen in our primary analysis 
should be viewed within the context of the num-
ber of days spent in hospital after HDLAI initia-
tion and before discharge: bed days appear to 
increase but this increase is seen during the index 
admission instead of after discharge. This may 
explain the difference between the findings in our 
primary analysis compared with both sensitivity 
analyses, which showed no reduction in bed days. 
Results for admissions in our primary analysis 
were supported by the sensitivity analysis, which 
also included the index admission.
Figure 4. Mean reduction in hospital admissions before and after haloperidol decanoate long-acting injection 
(main analysis).
Significant p values are shown in bold.
HDLAI, haloperidol decanoate long-acting injection.
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Treatment discontinuation
Long-acting injections (LAIs) do not differ from 
oral agents in tolerability.5 Previous studies have 
reported high discontinuation rates with oral 
haloperidol compared with second-generation 
agents.6–8 The efficacy and tolerability of HDLAI 
is comparable with other first generation LAIs.9 
Continuation with an antipsychotic medication is 
a proxy measure for treatment effectiveness.10 
Long-term treatment with any medication indi-
cates both a degree of patient tolerability and cli-
nician confidence in the efficacy of treatment. 
Conversely, poorly tolerated or ineffective treat-
ments are likely to be stopped. Interestingly, a 
similar proportion discontinued in our group to 
that reported by McEvoy and colleagues.1
We found that patients who started HDLAI 
because of nonadherence were more likely to stop 
treatment within 1 year whilst patients with a 
longer duration of illness were more likely to 
remain on treatment. A number of surveys have 
shown that patients prescribed LAIs understand 
the benefits of treatment in relapse prevention.11–14 
Patients who attend regular appointments for 
LAIs are more likely than infrequent attenders to 
believe that stopping maintenance treatment 
would result in a relapse. It is possible that 
patients in our study with a longer duration of ill-
ness were those who recognise the risks of treat-
ment discontinuation and were thus more likely 
to adhere to treatment.
Interestingly, lower rates of discontinuation have 
been reported with paliperidone palmitate at 1 
year in a similar population to those in our 
study.15,16 However, both these studies included 
patients who were outpatients stabilized on 
medication, as well as inpatients. A higher dis-
continuation rate may have been expected in our 
study, which included only patients admitted to 
an inpatient unit following a relapse in their 
mental state.
Strengths of our study
There are two main strengths of our study: the 
first is that the data collected accurately reflect 
the medication received by the patient. Many 
studies collect data from electronic patient notes 
or from population databases. We collected data 
on HDLAI prescription and administration 
from patient notes and prescription charts for 
patients each time the depot was due. We can 
therefore be certain that patients received the 
medication as recorded. The second is that our 
study did not influence clinical practice and as 
such, the data demonstrate naturalistic, real-
world outcomes.
Limitations
Mirror-image studies by design have some limi-
tations as described by Kishimoto and col-
leagues17 which would also apply to our study. 
For example, we did not randomly select 
patients to participate in the study, there was 
no control group and neither did we exclude 
patients who had previously tried HDLAI or 
clozapine. However, we believe studies such as 
this one are an accurate reflection of what hap-
pens in practice.
We included in our analysis all inpatients who 
started HDLAI. More than a third of the patients 
in our sample had either previously tried clozap-
ine or were considered to be treatment resistant. 
Nonetheless, discontinuation attributed to lack of 
efficacy was lower than expected, given the rates 
of treatment resistance in our sample.
We did not collect data on the use of anticholin-
ergic agents because this information was not 
available for the entire study duration.
Finally, our study included a relatively small 
number of patients. A similar study in a larger 
population is warranted.
Implications for practice
HDLAI was associated with good clinical out-
comes in patients who continued treatment at 1 
year. However, given the high rate of treatment 
discontinuation, HDLAI is best considered for 
those who are likely to continue treatment. Our 
study suggests that patients with a longer dura-
tion of illness and those initiated on HDLAI for 
reasons other than poor adherence are more likely 
to continue treatment.
Conclusion
HDLAI was associated with a high treatment dis-
continuation rate. Hospital admissions fell in the 
year after HDLAI but there was no change in bed 
days. Our study suggests that patients with a 
longer duration of illness and patients initiated on 
HDLAI for reasons other than poor adherence 
may benefit from HDLAI initiation.
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